Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Labeling Change Rule Is Most Prominent Item On Agency’s To-Do List

This article was originally published in The Pink Sheet Daily

Executive Summary

HHS’s semi-annual inventory of rulemaking actions under development includes six prescription drug-related rules.

Advertisement

Related Content

Gottlieb Nomination As US FDA Chief Could Signal Changes To Generic Approval Process
Gottlieb Nomination As US FDA Chief Could Signal Changes To Generic Approval Process
FDA Safety Labeling Change Guidance Seeks To Ease Class Confusion
Electronic Labeling Study By GAO Yields “No Consensus,” Avoids Cost Issue
FDA May Drop Generic Liability Shield, Allow ANDA Manufacturers To Change Labels
FDA “Xes” Letter Categories For Pregnancy Labels; Data Collection Drives Reg

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS075999

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel